$GRI

GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company developing therapies for serious diseases associated with dysregulated immune responses, including inflammatory, fibrotic and autoimmune disorders. Its lead candidate, GRI-0621, is an oral formulation of tazarotene that inhibits invariant natural killer T cells and is being developed for idiopathic pulmonary fibrosis. GRI-0803 is an oral activator of diverse natural killer T cells intended for autoimmune disorders, with initial development focused on lupus. The company also has a proprietary library of over 500 compounds, from which GRI-0803 was selected. GRI Bio retains global development and commercialization rights to its product candidates. It relies on third-party contract manufacturers for GRI-0621 used in preclinical studies and clinical trials. The company expects to earn money from commercializing approved products, either itself or with strategic partners, and may seek partners for some products and markets. GRI Bio is headquartered in La Jolla, California.

1
0
0

No SEC Form 4 filings for $GRI in the last 30 days.

See all $GRI insider activity →
Med

GRI Bio 3Q 2026: EPS ($0.69) — 10-Q Summary

GRI Bio reported no revenue and a narrowed net loss for 3Q 2026, citing reduced spending on GRI-0621 development. The Phase 2a trial met endpoints with no serious adverse events. FDA granted Orphan Drug Designation for GRI-0621. The company plans to file an IND application for GRI-0803 in 2027.

GRI Bio, Inc. (GRI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GRI Bio, Inc. (GRI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On November 4, 2026, at 11:00 a.m. Eastern Time, GRI Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockhol

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

GRI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning GRI (GRI Bio, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent GRI coverage spans financial news, technology and corporate actions.

What's driving GRI

AlphAI scores every news story that mentions GRI with an AI model for sentiment and relevance, and aggregates insider trades from GRI Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GRI

Score
$GRIMedAI 9/10

GRI Bio 3Q 2026: EPS ($0.69) — 10-Q Summary

GRI Bio reported no revenue and a narrowed net loss for 3Q 2026, citing reduced spending on GRI-0621 development. The Phase 2a trial met endpoints with no serious adverse events. FDA granted Orphan Drug Designation for GRI-0621. The company plans to file an IND application for GRI-0803 in 2027.

$GRILowShareholder vote

GRI Bio, Inc. (GRI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GRI Bio, Inc. (GRI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On November 4, 2026, at 11:00 a.m. Eastern Time, GRI Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockhol

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio (NASDAQ: GRI) said the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis (IPF). The company noted the designation may provide up to seven years of U.S. market exclusivity after approval, plus potential tax credits and fee waivers. GRI-0621 is an oral RARβ/γ agonist; a Phase 2a trial in 35 patients met endpoints, per the company.

GRI Bio (GRI) Schedule 13G/A: 90,475 shares represent 5.9% stake

GRI Bio, Inc. has filed an Amendment No. 2 to a Schedule 13G/A, reporting that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC beneficially own 90,475 shares of common stock, representing a 5.9% stake. These shares are issuable upon the exercise of a warrant held by Intracoastal, based on 1,445,029 shares outstanding as of January 29, 2026. The filing notes two additional warrants with 4.99% blocker provisions, which are excluded from this reported percentage.

GRI Bio receives UAE patent for inflammatory disease treatment

GRI Bio, Inc. has announced the receipt of a patent from the UAE Patent Office for its inflammatory disease treatment, covering type 2 diverse NKT cell agonists. This patent strengthens the company's intellectual property and supports its pipeline for inflammatory, fibrotic, and autoimmune diseases, despite significant financial headwinds indicated by a 93.5% drop in share price over the past year. The company is actively working to advance its drug development and improve its financial position, including recent capital raises and a planned reverse stock split.

New IPF trial data: GRI Bio CEO explains lung repair signals

GRI Bio CEO Marc Hertz discussed additional positive Phase 2a data for idiopathic pulmonary fibrosis (IPF) in a Virtual Investor segment, highlighting biomarker improvements related to fibrosis and lung repair. This announcement reiterates the company's recent focus on its clinical story, following other milestones like a reverse stock split, patent protection, and financial updates. Investors are encouraged to monitor the progression of these Phase 2a results into later-stage trials and the company's capital raising activities.

Related tickers